Rexahn Pharmaceuticals, Inc. (RNN) Sees Large Increase in Short Interest

Share on StockTwits

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 1,133,185 shares, a growth of 18.0% from the December 14th total of 960,272 shares. Approximately 3.0% of the company’s shares are sold short. Based on an average daily trading volume, of 357,783 shares, the days-to-cover ratio is currently 3.2 days.

NYSEAMERICAN RNN opened at $1.08 on Friday. Rexahn Pharmaceuticals has a one year low of $0.85 and a one year high of $2.70.

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last posted its earnings results on Monday, November 5th. The company reported ($0.17) EPS for the quarter, meeting analysts’ consensus estimates of ($0.17).

RNN has been the subject of a number of research analyst reports. HC Wainwright set a $20.00 price objective on shares of Rexahn Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 25th. B. Riley set a $8.00 price objective on shares of Rexahn Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 2nd. Ifs Securities upgraded shares of Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a report on Thursday, October 4th. Zacks Investment Research lowered shares of Rexahn Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 16th. Finally, Brookline Capital Management reiterated a “buy” rating on shares of Rexahn Pharmaceuticals in a report on Tuesday, November 27th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $8.75.

WARNING: “Rexahn Pharmaceuticals, Inc. (RNN) Sees Large Increase in Short Interest” was reported by Zolmax and is owned by of Zolmax. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://zolmax.com/investing/rexahn-pharmaceuticals-inc-rnn-sees-large-increase-in-short-interest/2819919.html.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

See Also: Initial Public Offering (IPO)

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

HyperQuant Price Tops $0.0028
HyperQuant Price Tops $0.0028
Flushing Financial Co.  Given Average Recommendation of “Hold” by Brokerages
Flushing Financial Co. Given Average Recommendation of “Hold” by Brokerages
Moneysupermarket.Com Group PLC  Receives Consensus Recommendation of “Hold” from Analysts
Moneysupermarket.Com Group PLC Receives Consensus Recommendation of “Hold” from Analysts
MCO  Hits Market Capitalization of $69.30 Million
MCO Hits Market Capitalization of $69.30 Million
LegacyTexas Financial Group Inc  to Issue Dividend Increase – $0.25 Per Share
LegacyTexas Financial Group Inc to Issue Dividend Increase – $0.25 Per Share
Cedar Realty Trust Inc  Plans Quarterly Dividend of $0.05
Cedar Realty Trust Inc Plans Quarterly Dividend of $0.05


Leave a Reply

 
© 2006-2019 Zolmax.